Source: FinanzNachrichten

Cimeio: Cimeio Therapeutics Presents Data for its CD52 Shielding Variant at ASGCT

-- Cimeio's CD52 shielding variant protects cells from depletion by Alemtuzumab while maintaining processing, cell surface expression and function -- -- Program serves as the basis for a novel tre...

Read full article »

Cimeio's Competitors | Cimeio's News | Cimeio's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Thomas Fuchs

CEO Approval Rating

- -/100

Cimeio is a Switzerland-based biotechnology company that develops and commercializes cell therapies for the treatment of genetic and autoimmune disorders.